File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1371/journal.pone.0157455
- Scopus: eid_2-s2.0-84976351543
- PMID: 27300551
- WOS: WOS:000377822200052
Supplementary
- Citations:
- Appears in Collections:
Article: Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A meta-analysis of randomized studies
Title | Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A meta-analysis of randomized studies |
---|---|
Authors | |
Issue Date | 2016 |
Citation | PLoS ONE, 2016, v. 11, n. 6, article no. e0157455 How to Cite? |
Abstract | © 2016 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Treatment related death (TRD) is the worst adverse event in chemotherapy and radiotherapy for patients with cancer, the reports for TRDs were sporadically. We aimed to study TRDs in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT), and determine whether high radiation dose and newer chemotherapy regimens were associated with the risk of TRD. Data from randomized clinical trials for locally advanced/unresectable NSCLC patients were analyzed. Eligible studies had to have at least one arm with CCRT. The primary endpoint was TRD. Pooled odds ratios (ORs) for TRDs were calculated. In this study, a total of fifty-three trials (8940 patients) were eligible. The pooled TRD rate (accounting for heterogeneity) was 1.44% for all patients. In 20 trials in which comparison of TRDs between CCRT and non-CCRT was possible, the OR (95% CI) of TRDs was 1.08 (0.70-1.66) (P = 0.71). Patients treated with third-generation chemotherapy and concurrent radiotherapy had an increase of TRDs compared to those with other regimens in CCRT (2.70% vs. 1.37%, OR = 1.50, 95% CI: 1.09-2.07, P = 0.008). No significant difference was found in TRDs between high (≥ 66 Gy) and low (< 66 Gy) radiation dose during CCRT (P = 0.605). Neither consolidation (P = 0.476) nor induction chemotherapy (P = 0.175) had significant effects with increased TRDs in this study. We concluded that CCRT is not significantly associated with the risk of TRD compared to non-CCRT. The third-generation chemotherapy regimens may be a risk factor with higher TRDs in CCRT, while high dose radiation is not significantly associated with more TRDs. This observation deserves further study. |
Persistent Identifier | http://hdl.handle.net/10722/267044 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhao, Jing | - |
dc.contributor.author | Xia, Yingfeng | - |
dc.contributor.author | Kaminski, Joseph | - |
dc.contributor.author | Hao, Zhonglin | - |
dc.contributor.author | Mott, Frank | - |
dc.contributor.author | Campbell, Jeff | - |
dc.contributor.author | Sadek, Ramses | - |
dc.contributor.author | Kong, Feng Ming | - |
dc.date.accessioned | 2019-01-31T07:20:21Z | - |
dc.date.available | 2019-01-31T07:20:21Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | PLoS ONE, 2016, v. 11, n. 6, article no. e0157455 | - |
dc.identifier.uri | http://hdl.handle.net/10722/267044 | - |
dc.description.abstract | © 2016 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Treatment related death (TRD) is the worst adverse event in chemotherapy and radiotherapy for patients with cancer, the reports for TRDs were sporadically. We aimed to study TRDs in non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy (CCRT), and determine whether high radiation dose and newer chemotherapy regimens were associated with the risk of TRD. Data from randomized clinical trials for locally advanced/unresectable NSCLC patients were analyzed. Eligible studies had to have at least one arm with CCRT. The primary endpoint was TRD. Pooled odds ratios (ORs) for TRDs were calculated. In this study, a total of fifty-three trials (8940 patients) were eligible. The pooled TRD rate (accounting for heterogeneity) was 1.44% for all patients. In 20 trials in which comparison of TRDs between CCRT and non-CCRT was possible, the OR (95% CI) of TRDs was 1.08 (0.70-1.66) (P = 0.71). Patients treated with third-generation chemotherapy and concurrent radiotherapy had an increase of TRDs compared to those with other regimens in CCRT (2.70% vs. 1.37%, OR = 1.50, 95% CI: 1.09-2.07, P = 0.008). No significant difference was found in TRDs between high (≥ 66 Gy) and low (< 66 Gy) radiation dose during CCRT (P = 0.605). Neither consolidation (P = 0.476) nor induction chemotherapy (P = 0.175) had significant effects with increased TRDs in this study. We concluded that CCRT is not significantly associated with the risk of TRD compared to non-CCRT. The third-generation chemotherapy regimens may be a risk factor with higher TRDs in CCRT, while high dose radiation is not significantly associated with more TRDs. This observation deserves further study. | - |
dc.language | eng | - |
dc.relation.ispartof | PLoS ONE | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A meta-analysis of randomized studies | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1371/journal.pone.0157455 | - |
dc.identifier.pmid | 27300551 | - |
dc.identifier.scopus | eid_2-s2.0-84976351543 | - |
dc.identifier.volume | 11 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | article no. e0157455 | - |
dc.identifier.epage | article no. e0157455 | - |
dc.identifier.eissn | 1932-6203 | - |
dc.identifier.isi | WOS:000377822200052 | - |
dc.identifier.issnl | 1932-6203 | - |